Not known Facts About YX-2-107
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge numerous intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Main trial objectives had been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis peop